Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth", which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report.
GBI Research's analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period. The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with many generics and branded generics drug products, is being seen as a significant growth opportunity for new patent protected products owing to high prevalence, progressive nature of the disease and considerably high unmet needs. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM.
Many multinational companies, such as Novartis, Eli Lilly, are engaged in setting up strategic marketing and distribution agreements with domestic players to improve their patient base and so the market share. Growing at a double digit year on year growth rate, the Indian anti-diabetics market is very promising and offers lucrative opportunities to both domestic as well as foreign pharmaceutical players.
Scope
Data and analysis on the Indian diabetes therapeutics market
Annualized market data for the diabetes therapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes.
Epidemiological data on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economic burden of diabetes.
Key drivers and restraints that have had a significant impact on the market.
Major trends and issues which are likely to have a significant impact on overall diabetes therapeutics market in India
Competitive landscape of the diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck, Abbott, USV, Sun Pharma, Biocon and Wockhardt.
Key M&A activities and licensing agreements, major deals that took place in last four years in Indian diabetes therapeutics market.
Reasons to buy
Align their product portfolio to the markets with high growth potential.
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents
TOC
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 10
2 Diabetes Therapeutics Market in India to 2018 - Overview 11
2.1 Diabetes Mellitus - A Global Overview 11
3 Diabetes Therapeutics Market in India - Introduction 12
3.1 Type 1 Diabetes Mellitus 12
3.1.1 People at Risk 12
3.1.2 Risk Factors for Type 1 Diabetes 12
3.1.3 Symptoms 12
3.2 Type 2 Diabetes Mellitus 13
3.2.1 People at Risk 13
3.2.2 Risk Factors for Type 2 Diabetes 13
3.2.3 Symptoms 13
3.3 Gestational Diabetes Mellitus 13
3.3.1 Risk Factors for Gestational Diabetes Mellitus 13
3.4 Diagnosis of Diabetes Mellitus 14
3.5 Diabetes Treatment Guidelines - India 15
3.5.1 Introduction 15
3.5.2 Prevention of Diabetes 15
3.5.3 Diabetes Treatment 15
3.6 Diabetes Mellitus Complications 16
4 Diabetes Therapeutics Market in India to 2018 - Major Drug Classes 17
4.1 Sulfonylureas 17
4.1.1 Introduction 17
4.1.2 Mechanism of Action 17
4.1.3 Major Drugs 18
4.2 Thiazolidinediones 18
4.2.1 Introduction 18
4.2.2 Mechanism of Action 18
4.2.3 Example 18
4.3 Biguanides 19
4.3.1 Introduction 19
4.3.2 Mechanism of Action 19
4.3.3 Drug Products 19
4.4 Meglitinides 20
4.4.1 Introduction 20
4.4.2 Mechanism of Action 20
4.4.3 Major Drugs 20
4.5 Alpha-Glucosidase Inhibitors 21
4.5.1 Introduction 21
4.5.2 Mechanism of Action 21
4.5.3 Major Drugs 21
4.6 Glucagon-Like Peptide Analogs and Agonists 22
4.6.1 Description 22
4.6.2 Mechanism of Action 22
4.6.3 Major Drugs 22
4.7 Dipeptidyl Peptidase-4 Inhibitors 22
4.7.1 Description 22
4.7.2 Mechanism of Action 22
4.7.3 Major Drugs 23
4.8 Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors 23
4.9 Insulin Preparations 23
4.9.1 Introduction 23
4.9.2 Types of Insulin 23
5 Diabetes Therapeutics Market in India to 2018 - Epidemiology 25
5.1 Introduction 25
5.2 Diabetes Population in India 27
5.3 Diagnosed Population 29
5.4 Treated Population 29
6 Diabetes Therapeutics Market in India to 2018 - Revenue Forecasts 30
6.1 Introduction 30
6.1.1 Oral Anti-Diabetics Market 31
6.1.2 Insulin Market 31
6.2 Annual Cost of Therapy 32
7 Diabetes Therapeutics Market in India to 2018 - Economic Burden of Diabetes in India 33
7.1 Economic Burden of Diabetes in India 33
7.1.1 Introduction 33
7.1.2 Healthcare Expenditure on Diabetes in India 33
7.2 Collaborative Efforts Necessary to Address the Rising Burden of Diabetes 34
8 Diabetes Therapeutics Market in India to 2018 - Drivers and Barriers 35
8.1 Market Drivers 35
8.1.1 Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India 35
8.1.2 Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy 35
8.1.3 Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies 36
8.2 Market Barriers 36
8.2.1 Low Diagnosis and Prescription Rate 36
8.2.2 Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure 36
8.2.3 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes 37
9 Diabetes Therapeutics Market in India to 2018 - Unmet Needs 38
9.1 Introduction 38
9.2 High Cost of Therapy and Drug Safety Issues Affect Patient Compliance 38
9.3 Unmet Need Creates Opportunities for Pharmaceutical Companies 38
10 Diabetes Therapeutics Market in India to 2018 - Product Pipeline Analysis 39
10.1 Profiles of Promising Molecules in R&D Development 40
Figure 21: GBI Research Market Forecasting Model 73
Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth published by GBI Research in January 22, 2013. This report consists of Pages: 74 and the price starts from US $ 3500.
Press Release
Growing Diabetes Population in India Offers Lucrative Opportunities
January 29th, 2013
Global Information Inc. would like to present a new market research report, "Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth" by GBI Research.
The Indian diabetes therapeutics market is one of the fastest growing market segments in India. A growing patient population and increased demand for effective medication are offering both domestic and Multinational Companies (MNCs) promising opportunities.
Growing Diabetes Population in India Offers Lucrative Opportunities
With approximately 61.3 million diabetics in 2011, India presents a promising opportunity for pharmaceutical companies with anti-diabetic product portfolios. India, after China, is the second diabetes capital of the world. As per the International Diabetes Federations (IDFs) estimation, the diabetes population in the country is expected to reach approximately 101 million by 2030 (IDF, 2011a). It stood at 40.9 million in 2007, 50.8 million in 2010 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 2.7% from 2011 to 73.8 million by 2018.
The number of patient with diabetes, predominantly type 2 diabetes, continues to increase at an alarming rate, mainly attributed to sedentary lifestyles, the adoption of Westernized culture and increased longevity. This offers many promising opportunities to pharmaceutical companies in terms of launching new anti-diabetic therapies and offsetting the loss of revenues and market share, if any, in the established markets.
Anti-Diabetes Market Set to Witness Double-Digit Growth in the Forecast Period
Growing at a double-digit year-on-year growth rate, the Indian anti-diabetics market is very promising and offers lucrative opportunities to both domestic and foreign pharmaceutical players.
GBI Researchs analysis has revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% to $1,446m in 2018. The key growth drivers are the large and growing diabetes population in the country and anticipated launch of many first-in-class and novel molecules during the forecast period.
In 2011, the overall anti-diabetic market was dominated by type 2 diabetes therapeutics, which accounted for approximately 87% of the market by value. The overall type 2 diabetes therapeutics market is segmented into oral anti-diabetics and insulin, which accounted for 64% and 36% respectively in 2011. The key market drivers would be the large and growing diabetes population, growing obese and geriatric populations, and rapid market adoption of drugs from classes such as Dipeptidyl Peptidase-4 (DPP-4) inhibitors, Glucagon-Like Peptides (GLP-1) and Sodium-Glucose Transport Proteins (SGLT1), among others. Low treatment-seeking and diagnosis rates, poor compliance to medical care, rising healthcare costs and an increasingly competitive market are some of the key hurdles for the domestic diabetes market.
Strategic Consolidations Underway to Improve Growth Prospects
A huge and rising diabetes population and good growth prospects have made India a highly lucrative opportunity. Many MNCs are engaged in setting up strategic marketing and distribution agreements with domestic players to improve their patient base and market share.
MNCs rising interest in the emerging markets is indicated by the joint venture between Sun Pharma and Merck to bring new anti-diabetics to emerging markets, the USV-Novartis collaboration for the marketing of Galvus, the Lupin-Eli Lilly alliance for the marketing of insulin, and collaborations between Eli Lilly and Boehringer Ingelheim.
Through strategic consolidations such as these, MNCs are trying to expand their patient base by widening their reach in the domestic market. More aggressive marketing and a wider reach could potentially increase their market share and also develop a platform from which to ensure R&D success in terms of pipeline products. Strategic collaborations would help MNCs to market their products throughout India and overturn the competition in the established markets. They would also help domestic companies as having a MNC with sufficient resources in place on their side means strong sales forces and manufacturing capabilities. Given the large market and predicted double-digit growth rate, more strategic consolidations are expected to follow during the forecast period.
Strong R&D Product Pipeline for Diabetes to Drive the Market in the Forecast Period
The strong R&D product pipeline and the anticipated launch of novel first-in-class and me-too molecules and new insulin formulations will drive the anti-diabetic market in the future.
The R&D product pipeline for Diabetes Mellitus (DM), dominated by Oral Anti-Diabetic (OAD) agents, consists of 194 molecules at various stages of clinical development. The majority (72%) are in Phase III, followed by 15% in Phase II, 7% in Phase I, 5% in Phase II/III and 1% in Phase I/II.
Paradoxically, the type 2 diabetes therapeutics market, which is crowded with generic and branded generic drug products, is being viewed as a significant growth opportunity for newly patent-protected products, owing to high disease prevalence, its progressive nature, and the considerably high unmet need. Of all R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM. The R&D product pipeline comprises many first-in-class molecules such as dapagliflozin, empagliflozin and canagliflozin; and a number of me-too molecules such as alogliptin, syncria, lixisenatide, Bydureon (a biobetter of Byetta); and new insulin formulations such as IN-105, an oral insulin, from Biocon and degludec, an ultra long-acting insulin from Novo Nordisk. The anticipated launch of some of these pipeline molecules will improve treatment and compliance rates and will drive the anti-diabetic market in the forecast period.
